Centene (CNC) Gets a Hold from Wells Fargo
In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Hold rating on Centene, with a price target of $44.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Baxter covers the Healthcare sector, focusing on stocks such as Centene, CVS Health, and Humana. According to TipRanks, Baxter has an average return of -1.7% and a 41.85% success rate on recommended stocks.
In addition to Wells Fargo, Centene also received a Hold from Deutsche Bank ‘s George Hill in a report issued on February 10. However, yesterday, Truist Financial reiterated a Buy rating on Centene (NYSE: CNC).
Based on Centene’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $49.73 billion and a GAAP net loss of $1.1 billion. In comparison, last year the company earned a revenue of $40.81 billion and had a net profit of $283 million
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CNC in relation to earlier this year. Most recently, in December 2025, Kenneth Burdick, a Director at CNC sold 66,007.00 shares for a total of $2,575,601.44.
Read More on CNC:
Disclaimer & DisclosureReport an Issue
- Centene price target raised to $44 from $43 at Wells Fargo
- DME Capital buys BKV, boosts PG&E in Q4
- Balanced Outlook: Raising Long-Term EPS and Target Price While Medicaid Headwinds Justify a Hold Rating
- Centene price target raised to $39 from $32 at Deutsche Bank
- CVS, ELV, CNC: Health Insurer Stocks Under Pressure as U.S. Expands Fraud Probe
